About BioCardia Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.biocardia.com/
Frequently Asked Questions
What is the 52-week range for BCDA?
The 52-week high is $1.8 and the 52-week low is $0.75.
What is the P/E ratio for BCDA?
The P/E ratio data is currently unavailable.
What is the dividend yield for BCDA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -221.68%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -1985.85%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 14.82.
Analyst Recommendation Trends
Wall Street analyst consensus for BCDA over the last few months:
Latest BCDA News
BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter
SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart. In May 2026, the Company and FDA met and
BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart
BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones. CardiAMP® Autologous Cell Therapy for Ischemic Heart Failure BioCardia is working towards a Shonin pre-market regulatory submission to Japan’s Pharmaceutical and Medical Device Agency (PMDA) in Q4 2026. The Company has recently provided detailed
BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System
BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term milestones.BioCardia is working
BioCardia Shares Fall 10% After Hours: Here's Why
BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.
Top movers in Monday's after hours session
The US market regular session of Monday is over, let's have a look at the top gainers and losers in the after hours session today.
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday's after-market session. The market value of their outstanding shares is at $8.3 million. Alaunos Therapeutics
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference
SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026. Dr. Altman will provide an update
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-23 | Altman Peter | +1,900 | $1.05 | $1,995 |
| 2026-09-03 | Altman Peter | +800 | $1.09 | $872 |
| 2026-08-17 | Altman Peter | +5,400 | $0.93 | $5,022 |
| 2026-08-13 | Altman Peter | +1,900 | $0.92 | $1,748 |
| 2026-07-29 | Altman Peter | +5,000 | $0.78 | $3,900 |
| 2026-07-17 | Altman Peter | +500 | $0.83 | $415 |
| 2026-07-15 | Altman Peter | +1,500 | $0.86 | $1,290 |
| 2026-07-14 | Altman Peter | +2,800 | $0.88 | $2,464 |
| 2026-07-10 | Altman Peter | +1,000 | $0.94 | $940 |
| 2026-07-09 | Altman Peter | +1,000 | $0.9 | $900 |
| 2026-07-08 | Altman Peter | +5,500 | $0.97 | $5,335 |
| 2026-07-08 | Altman Peter | +5,400 | $0.9645 | $5,208 |
| 2026-07-06 | Facteau Bill | +8,000 | - | - |
| 2026-07-06 | Slosman Marvin | +8,000 | - | - |
| 2026-07-06 | Blank Andrew Scott | +8,000 | - | - |
| 2026-07-06 | Allen Jim L. | +8,000 | - | - |
| 2026-07-06 | McClung David | +41,501 | - | - |
| 2026-07-06 | Altman Peter | +57,688 | - | - |
| 2026-07-06 | GILLIS EDWARD M | +29,442 | - | - |
| 2026-07-06 | MOYES JAY M | +8,000 | - | - |
| 2026-07-06 | STERTZER SIMON H | +8,000 | - | - |
| 2026-07-02 | McClung David | -23,125 | $1.24 | $28,675 |
| 2026-07-02 | Altman Peter | -54,606 | $1.24 | $67,711 |
| 2026-07-02 | GILLIS EDWARD M | -17,269 | $1.24 | $21,414 |
| 2026-06-29 | McClung David | +60,483 | $1.2 | $72,580 |
| 2026-06-29 | Altman Peter | +110,625 | $1.2 | $132,750 |
| 2026-06-29 | GILLIS EDWARD M | +39,521 | $1.2 | $47,425 |
| 2026-06-23 | STERTZER SIMON H | +39,000 | $1 | $39,000 |
| 2026-06-22 | STERTZER SIMON H | +70,200 | $0.92 | $64,584 |
| 2026-06-18 | Altman Peter | +800 | $0.96 | $768 |
| 2026-06-17 | Altman Peter | +1,500 | $0.85 | $1,275 |
| 2026-06-09 | Altman Peter | +5,000 | $0.85 | $4,250 |
| 2026-05-20 | Altman Peter | +1,500 | $0.92 | $1,380 |
| 2026-05-19 | Altman Peter | +200 | $0.95 | $190 |
| 2026-05-18 | Altman Peter | +5,700 | $0.92 | $5,244 |
| 2026-05-15 | Altman Peter | +5,100 | $1.02 | $5,202 |
| 2026-04-29 | Altman Peter | +5,000 | $1.11 | $5,550 |
| 2026-04-21 | Altman Peter | +400 | $1.23 | $492 |
| 2026-04-20 | Altman Peter | +600 | $1.23 | $738 |
| 2026-03-25 | Altman Peter | +300 | $1.22 | $366 |
| 2026-03-24 | Altman Peter | +600 | $1.24 | $744 |
| 2026-02-04 | Altman Peter | +5,000 | $1.13 | $5,650 |
| 2026-01-21 | Altman Peter | +300 | $1.34 | $402 |
| 2026-01-20 | Altman Peter | +600 | $1.32 | $792 |
| 2025-12-17 | Altman Peter | +900 | $1.3 | $1,170 |
| 2025-12-16 | Altman Peter | +200 | $1.37 | $274 |
| 2025-12-08 | Facteau Bill | +12,000 | - | - |
| 2025-12-08 | Slosman Marvin | +12,000 | - | - |
| 2025-12-08 | Blank Andrew Scott | +12,000 | - | - |
| 2025-12-08 | Allen Jim L. | +12,000 | - | - |
| 2025-12-08 | McClung David | +27,000 | - | - |
| 2025-12-08 | McClung David | +29,339 | $1.37 | $40,194 |
| 2025-12-08 | McClung David | +58,276 | $1.37 | $79,838 |
| 2025-12-08 | GILLIS EDWARD M | +20,000 | - | - |
| 2025-12-08 | GILLIS EDWARD M | +15,172 | $1.37 | $20,786 |
| 2025-12-08 | GILLIS EDWARD M | +38,078 | $1.37 | $52,167 |
| 2025-12-08 | MOYES JAY M | +12,000 | - | - |
| 2025-12-08 | STERTZER SIMON H | +12,000 | - | - |
| 2025-12-08 | Altman Peter | +38,000 | - | - |
| 2025-12-08 | Altman Peter | +56,484 | $1.37 | $77,383 |
| 2025-12-08 | Altman Peter | +106,588 | $1.37 | $146,026 |